- Home
- / Vir Biotechnology
Vir Biotechnology
Stock Price
$7.6
2024-10-29
Market Capitalization
$1 B
2024-10-29
Revenue
$68.6 M
FY, 2025
Vir Biotechnology Summary
Company Summary
- Overview
- Vir Biotechnology is a biopharmaceutical company that develops therapies for infectious diseases and cancer. It develops antibodies and protease-releasable masking technologies for diseases including chronic hepatitis delta, COVID-19, Ebola, and certain solid tumors. The company serves organizations in the infectious disease and oncology fields.
- Type
- Public
- Status
- Active
- Founded
- 2016
- HQ
- San Francisco, CA, US | view all locations
- Website
- https://www.vir.bio/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Aine Hanly, Chief Technology Officer
Howard Horn, CFO
Antonio Lanzavecchia, Senior Vice President and Senior Research Fellow
Operating MetricsView all
Scientific Collaborations
5
Oct, 2019
Drugs in Development
5
Oct, 2019
Technology Platforms
4
Oct, 2019
LocationsView all
2 locations detected
San Francisco, CA HQ
United States
1800 Owens St #900
Bellinzona, TI
Switzerland
Via dei Gaggini 3
Vir Biotechnology Financials
Summary Financials
- Revenue (Q1, 2026)
- ($29.0K)
- Net income (Q1, 2026)
- ($125.7M)
- Cash (Q1, 2026)
- $274.2M
- EBIT (Q1, 2026)
- ($132.3M)
- Enterprise value
- $852.3M